III. New Claim 62

Applicants have added claim 62 directed to the examples described in the specification, see specification as filed page 13. Therefore claim 62 finds support in the specification and does not add new matter.

IV. Conclusion

Based on the above arguments, deletion of claims 52 and 54-61, and new claim 62, Applicants respectfully request that the Examiner allow claim 62.

14 -

Agouron Pharmaceuticals Inc. Patent Dept. 10777 Science Center Drive San Diego, CA 92121 (858) 638-6117 Respectfully submitted,

Elsa Djuardi

Attorney for Applicants

Reg. No. 45,963